Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MELBOURNE, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the independent Data and Safety Monitoring Board (DSMB) for the Company’s ongoing Phase...
-
MELBOURNE, Australia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce the grant of Japanese Patent Number 6408492 covering its OPT-302 soluble VEGFR-3 (sVEGFR-3)...
-
MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, is pleased to...
-
MELBOURNE, Australia, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today...
-
MELBOURNE, Australia, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to provide an update on...
-
MELBOURNE, Australia, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing innovative biologic therapies to treat retinal diseases, today...
-
MELBOURNE, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
-
MELBOURNE, Australia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to announce that it will host...
-
MELBOURNE, Australia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat...
-
MELBOURNE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, today...